Knockdown of MSRB1 significantly inhibits malignant tumor phenotypes, suggesting that it can be used as a new therapeutic target for CRC (Chen, Yang, et al. 2021; Li et al. 2018; He et al. 2018). This evidence concerns the gene MSRB1 and colorectal carcinoma.